NanoStem Cell, a division of NanoInk,
Inc., announced today that Professor John Hunt of the UK Centre for Tissue
Engineering (UKCTE) at the University of Liverpool will present the results
of an ongoing, collaborative research project leveraging NanoInk's proprietary
Dip Pen Nanolithography® (DPN®) technology to create homogenous nanopattern
biochips and control cell functionality in a predictable and reproducible manner.
Professor Duncan Graham of the Centre of Molecular NanoMetrology at the University
of Strathclyde in Glasgow, Scotland is also collaborating on the project. Professor
Hunt will present this exciting data at the NanoScience Technology Institute
Nanotech Conference + Expo 2009 being held in Houston, Texas, Sunday, May
3, to Thursday, May 7.
The data will highlight that the DPN-created nanopattern chips provide unparalleled
control of stem cell differentiation including keeping adult stem cells in an
undifferentiated form as well as inducing differentiation to a homogenous population
of a targeted primary cell type, depending on the chemistry and topography of
"Through our collaborative efforts and use of our DPN nanopatterning technology,
we will be able to provide pharmaceutical and biotech companies with access
to large and renewable sources of homogeneous populations of differentiated
stem cells for drug discovery, drug development and high throughput screening,"
said Haris Jamil, Vice President of NanoInk's NanoStem Cell Division.
"We are very excited about the results we are generating in this project,"
said Professor John Hunt, UKCTE. "The data shows that NanoInk's proprietary
Dip Pen Nanolithography technology can be used to present environments suitable
for the guidance and control of stem cells for development into functional phenotypically
defined populations of cells."
"The project and subsequent data generated up to now are impressive. There
is great potential in this project and it is definitely worth talking about,"
said Professor Duncan Graham, Centre of Molecular NanoMetrology at the University
of Strathclyde. "Each component of this collaboration is essential in moving
the project forward and generating tangible results in drug discovery, drug
development and regenerative medicine."
"The results we are generating in this exciting effort will generate substantial
cost savings," said James M. Hussey, chief executive officer of NanoInk.
"But more importantly, the research moves us a step closer toward providing
options for patients that may require a regenerative approach to treatment."
The project results follow an announcement in March 2009 detailing the joint
research and licensing agreements between NanoInk, the UKCTE at the University
of Liverpool in Liverpool, England, and the Centre of Molecular NanoMetrology
at the University of Strathclyde in Glasgow, Scotland.
Professor Hunt's presentation will be on Wednesday, May 6, at 10:30 a.m. Central,
at the George R. Brown Convention Center in room 370BE.
For more information about the NSTI Nanotech Conference & Expo 2009, please